Status:
RECRUITING
Lidocaine Infusion in Pancreatic Cancer
Lead Sponsor:
University of Illinois at Chicago
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
This study elucidates the effects of the intravenous (IV) lidocaine infusion on the biology of pancreatic circulating tumor cells (CTCs) isolated from patients undergoing robotic pancreatectomy for al...
Detailed Description
The primary objective of this study is to determine the effect of IV lidocaine infusion on various enzymatic activities and associated pathways in isolated CTCs as well as the number of CTCs during th...
Eligibility Criteria
Inclusion
- Has histologically or cytologically confirmed adenocarcinoma of the pancreas that is considered resectable as well as other types of pancreatic cancer (malignant endocrine and exocrine tumors)
- Has measurable disease, defined as at least 1 tumor that fulfills the criteria
- Patients diagnosed with resectable cancer, but upon initial phase of surgical exploration found to have metastatic disease
- Has read, understood and signed the informed consent form (ICF) approved by the Independent Review Board/Independent Ethics Committee (IRB/IEC)
- Prior systemic treatments for metastatic disease are permitted, including targeted therapies, biologic response modifiers, chemotherapy, hormonal therapy, or investigational therapy.
Exclusion
- Has American Society of Anesthesiologists (ASA) physical status \> 3
- Has hypersensitivity or allergy to amide-linked local anesthetics
- Has a second or third degree heart block
- Has severe sinoatrial block
- Is currently being treated with any of the following class I antiarrhythmic drugs; quinidine, flecainide, disopyramide, or procainamide
- Has been treated with amiodarone in the past
- Has Adams-Stoke syndrome
- Has Wolff-Parkinson-White syndrome
- Has a history of blood clots, pulmonary embolism, or deep vein thrombosis unless controlled by anticoagulant treatment
- Has a known history of human immunodeficiency virus (HIV) positivity or untreated and uncontrolled hepatitis B or C
Key Trial Info
Start Date :
November 8 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2026
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT04048278
Start Date
November 8 2018
End Date
January 1 2026
Last Update
March 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Illnois at Chicago
Chicago, Illinois, United States, 60612